At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 14 enrolled
Drug / intervention
Pemigatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United·interventional·Posted Sep 19, 2019·Updated Feb 21, 2024
In Brief
A Phase 2 clinical trial evaluating Pemigatinib and Quality-of-Life Assessment for FGFR1 Gene Amplification and 18 related conditions. Targeting 14 participants across 6 sites.
Detailed Summary
This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR2 Gene Translocation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, FGFR3 Gene Translocation, Metastatic Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2UnknownOverdue
2020202120222023202420252026
First PostedSep 2019
Enrollment StartAug 2020
Primary CompletionMay 2022
Study CompletionDec 2025
TodayJul 2026
First PostedSep 19, 2019
Enrollment StartAug 31, 2020
Primary CompletionMay 13, 2022
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.8 years ago
Interventions
Pemigatinibdrug
Given PO
Quality-of-Life Assessmentother
Ancillary studies